Molecular Oncology
A section of International Journal of Molecular Sciences (ISSN 1422-0067).
Section Information
This section of the International Journal of Molecular Sciences (IJMS) aims to rapidly publish contributions novel findings in research to molecular aspects of all types of human cancers. This section ranges from basic sciences to preclinical research. We encourage submission of high-quality manuscripts that provide novel mechanistic insights and details of the molecular signatures of oncogenic transformation. We also encourage submission of high-quality manuscripts that focus on translating basic molecular knowledge to new clinical applications in oncology. The scope of this section includes, but is not limited to, the following:
- Biological processes, like gene activity in relation with specific molecular pathways, in the development and progression of cancers
- Mechanisms of metastasis (vascular and lymphatic dissemination and seeding)
- Molecular interactions in the tumor microenvironment, including tumor-immune interactions
- Genomic profiling of human cancers and any other ‘systems biology’ approaches in understanding development of human cancers
- Preclinical research that leads to novel therapies derived from molecular processes and cellular interactions, including gene therapy, therapy based on biologicals, hormonal therapy, and cancer vaccines and other types of immunotherapies
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Molecular Pathology of Lung Cancer: Current Status and Perspectives (Deadline: 13 July 2022)
- Attacking Cancer Progression and Metastasis 3.0 (Deadline: 30 July 2022)
- New Strategies to Overcome Resistance to Chemotherapy and Immune System in Cancer 3.0 (Deadline: 31 July 2022)
- The Role of Post-translational Modifications in Chromatin and Cancer (Deadline: 31 July 2022)
- Advances in Genome Regulation in Cancer (Deadline: 31 July 2022)
- New Molecular Targets in Lung Cancer (Deadline: 31 July 2022)
- Primary Intraocular Tumors–Molecular Mechanisms, Novel Therapeutic Strategies and Targets (Deadline: 31 July 2022)
- Novel Therapeutic Strategies for Cancer (Deadline: 31 July 2022)
- Lipid as a Cancer Therapeutic Target 2.0 (Deadline: 31 July 2022)
- Study on “Stemness” of Cancer Cells and Main Cause of Cancer Relapse after Standard Therapy (Deadline: 31 July 2022)
- Prostate Cancer: Pathology, Pathobiology and Therapy (Deadline: 31 July 2022)
- Antitumor Agents from Marine Natural Products (Deadline: 31 July 2022)
- Advancing the Emerging Concept of Drug Tolerant Persister (DTP) Cells in Lung Cancer (Deadline: 31 July 2022)
- Evolution of Cancer Pharmacological Treatment: Natural Compounds as Adjuvants for Cancer Treatments (Deadline: 31 July 2022)
- MicroRNAs and Long Non-coding RNAs in Tumor Microenvironment 2.0 (Deadline: 31 July 2022)
- The Role of DNA Damage and Repair in Cancer (Deadline: 31 July 2022)
- The Influence of Genetics and Environmental Risk Factors in Cutaneous and Mucosal Neoplasms 2.0 (Deadline: 31 July 2022)
- NK Cells, Immune Response in Pathology and Cancer (Deadline: 31 July 2022)
- Cancer Metabolism: Molecular Targeting and Implications for Therapy (Deadline: 31 July 2022)
- DNA Repair in Cancers 2.0 (Deadline: 31 July 2022)
- Calcium Signaling and Calcium Transport in Tumors (Deadline: 31 July 2022)
- New Insights into the Pathophysiology of Gynecological Cancers (Deadline: 31 July 2022)
- Drug Repurposing for Cancer Therapies (Deadline: 31 July 2022)
- Non-coding RNAs and Novel Therapeutic Targets in Human Cancers (Deadline: 1 August 2022)
- Multiple Myeloma: Focus on Molecular and Epigenetic Aspects (Deadline: 15 August 2022)
- Therapy-Promoted Cancer Repopulation and Acquired Cell-Resistance: Beyond Gene Mutation (Deadline: 15 August 2022)
- Transcription Factors in Cancer 2.0 (Deadline: 31 August 2022)
- Molecular Determinants of Neuroblastoma 2.0 (Deadline: 31 August 2022)
- Photodynamic Therapy as Important Tool for Biological Breakthroughs (Deadline: 31 August 2022)
- Advances in Hepatocellular Carcinoma (Deadline: 31 August 2022)
- Molecular Mechanisms of Tumor Suppressor Genes (Deadline: 31 August 2022)
- Innovative Strategies and Treatment Options for Head and Neck Cancer (Deadline: 31 August 2022)
- Mitochondrial Plasticity in Cancer (Deadline: 31 August 2022)
- A New Frontier on Cancer Invasion and Metastasis Research 2022 (Deadline: 31 August 2022)
- Lipids as Supporting Therapy in Cancer (Deadline: 31 August 2022)
- Combating Drug Resistance in Cancer—from Novel Biomarkers to Enhanced Therapeutic Efficacy (Deadline: 31 August 2022)
- Alternative Splicing in Cancer: Role, Mechanisms and Impact (Deadline: 31 August 2022)
- Natural Compounds with Cancer-Selective Toxicity (Deadline: 31 August 2022)
- New Insights into Endometrial Cancer 2022 (Deadline: 31 August 2022)
- Recent Advances in Targeted Drug Discovery and Delivery in Cancer (Deadline: 31 August 2022)
- Noncoding RNAs as New Instruments in the Orchestration of Cell Death and Cancer Therapy Resistance 2.0 (Deadline: 31 August 2022)
- Advances in Molecular Pathogenesis and Targeted Therapies for Myeloid Neoplasms (Deadline: 31 August 2022)
- Signal Pathways in Cancer (Deadline: 31 August 2022)
- Advances in Agressive Prostate Cancer (Deadline: 31 August 2022)
- The Discovery, Synthesis and Development of Cancer Therapeutic Agents (Deadline: 31 August 2022)
- Celluar and Molecular Mechanisms Involved in Prostate Cancer Cell Migration and Invasion (Deadline: 31 August 2022)
- Emerging Molecular Mechanisms of Cell Cycle Regulation: Opportunities for Cancer Intervention? (Deadline: 31 August 2022)
- Lung Cancer: From Molecular Basis to Genome-Guided Therapy and Immunotherapy (Deadline: 31 August 2022)
- Extracellular Matrix and Cancer: An Intricate Affair (Deadline: 31 August 2022)
- Immunotherapy for Hematological and Solid Cancers (Deadline: 31 August 2022)
- The Role of Notch Signaling Activation and Its Cross-Talk with Other Pathways in Hematological Malignancies (Deadline: 15 September 2022)
- Gliomas: From Molecular Mechanisms to Therapeutic Approaches (Deadline: 30 September 2022)
- Molecular Interactions between Cancer Cells and Tumor Microenvironment 2.0 (Deadline: 30 September 2022)
- Ion Channels as Therapeutic Target in Cancer (Deadline: 30 September 2022)
- Molecular Drivers of Responsiveness to Cancer Immunotherapy (Deadline: 30 September 2022)
- Role of MicroRNAs in Cancer Development and Treatment (Deadline: 30 September 2022)
- Molecular Alterations in Gastrointestinal Pre-invasive Lesions 2.0 (Deadline: 30 September 2022)
- Molecular Advances in Cancer Therapy (Deadline: 30 September 2022)
- State-of-the-Art Molecular Oncology in Brazil (Deadline: 30 September 2022)
- Molecular Mechanisms and Targeted Therapies in Gastrointestinal Cancer 2.0 (Deadline: 30 September 2022)
- Extracellular Vesicles and Their Role in Immunomodulation and Cancer (Deadline: 30 September 2022)
- Oncogenic Signaling of Growth Factor Receptors in Cancer 2.0: Mechanisms and Therapeutic Opportunities (Deadline: 30 September 2022)
- Current Use and Perspectives of Molecular Assessment in Breast Cancer (Deadline: 30 September 2022)
- Molecular Mechanisms and Therapies of Colorectal Cancer (Deadline: 30 September 2022)
- Molecular Signal Transduction in Tumor Progression and Metastasis (Deadline: 30 September 2022)
- Novel Therapeutic Treatments to Target Glioblastoma Intratumoral Heterogeneity and Plasticity 2.0 (Deadline: 30 September 2022)
- Epigenetic and Transcriptional Mechanisms in Gynecologic Cancers Development, Progression, and Resistance to Treatment (Deadline: 30 September 2022)
- Molecular Pathogenesis of T Cell Lymphomas (Deadline: 30 September 2022)
- Epigenetic and Transcriptional Networks in Soft Tissue Sarcomas (Deadline: 30 September 2022)
- Role of HIF-1 in Cancer Metabolism and Progression (Deadline: 30 September 2022)
- Advanced Research in Acute Myeloid Leukemia (Deadline: 30 September 2022)
- Molecular Diagnostics, Pathology and Biomarkers of Gastrointestinal Neoplasms (Deadline: 30 September 2022)
- Macrophages in the Glioblastoma Tumor Microenvironment (Deadline: 30 September 2022)
- Circulating Tumor Cells: Pathological, Molecular and Functional Characteristics 3.0 (Deadline: 30 September 2022)
- Extracellular Matrix in the Tumor Microenvironment 2.0 (Deadline: 30 September 2022)
- Molecular Biology of Melanoma 2.0 (Deadline: 30 September 2022)
- Sarcoma (Deadline: 30 September 2022)
- Novel Players in Chemioresistance as New Targets for Cancer Treatment (Deadline: 30 September 2022)
- Gene and Cell-Based Cancer Therapies (Deadline: 30 September 2022)
- TNIK in Cancer Progression and Therapeutic Opportunities (Deadline: 30 September 2022)
- Advances in Spine Oncology 2.0 (Deadline: 30 September 2022)
- Cancer Immunotherapy: Recent Advances and Prospects (Deadline: 30 September 2022)
- Bioactive Phytochemicals for Cancer Prevention and Treatment 3.0 (Deadline: 30 September 2022)
- Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers (Deadline: 30 September 2022)
- Altered RNA Processing in Tumor Pathogenesis and Therapy (Deadline: 30 September 2022)
- Natural Bioactives and Phytochemicals in Cancer Prevention 2.0 (Deadline: 30 September 2022)
- Mutant p53 in Cancer Progression and Personalized Therapeutic Treatments (Deadline: 10 October 2022)
- Molecular Research and Treatment of Breast Cancer 2.0 (Deadline: 15 October 2022)
- Mitochondria and Cancer: The Giant Screen View (Deadline: 15 October 2022)
- Molecular Targets of Anticancer Therapy (Deadline: 15 October 2022)
- Pleiotropic Effect of β-Adrenergic Receptors in Human Cancers and Other Human Diseases II (Deadline: 20 October 2022)
- Targeting PI3K/AKT/mTOR Signaling Pathway in Cancer (Deadline: 20 October 2022)
- Gastric Cancer: Molecular Pathways and Candidate Biomarkers 4.0 (Deadline: 25 October 2022)
- Microbiota and Cancer 2.0 (Deadline: 30 October 2022)
- Breast Cancer, Metastatic Breast Cancer, Therapeutic Approaches (Deadline: 31 October 2022)
- Oral Fibrosis and Oral Cancer: From Molecular Targets to Therapeutics 2.0 (Deadline: 31 October 2022)
- Adrenocortical Cancer and Molecular Target Inhibitors: From the Molecular Basis to the Clinical Experience (Deadline: 31 October 2022)
- Peptides and Their Conjugates for Cancer Therapy (Deadline: 31 October 2022)
- Clarification of Mechanism of Carcinogenesis 2.0 (Deadline: 31 October 2022)
- Liver Cancer 2.0 (Deadline: 31 October 2022)
- Research into Using Natural-Product-Related Medicines for Cancer (Deadline: 31 October 2022)
- The Role of Exosomes in Cancer Diagnosis and Therapy (Deadline: 31 October 2022)
- Molecular Target and Action Mechanism of Anti-cancer Agents 2.0 (Deadline: 31 October 2022)
- Implication of Nanoparticles in Cancer Therapy Research (Deadline: 31 October 2022)
- Immune, Inflammatory and Metabolic Mechanisms in Cancer (Deadline: 31 October 2022)
- The Bidirectional Relationship between Cancer Epigenetics and Metabolism (Deadline: 31 October 2022)
- Deciphering the Therapeutic Resistance of Hematologic Malignancies (Deadline: 31 October 2022)
- Proteomics and Metabolomics Approaches on Cancer Research (Deadline: 31 October 2022)
- Molecular Research in Squamous Cell Cancer of the Head and Neck (Deadline: 31 October 2022)
- Current Concepts and Advances in Diagnosis and Treatment of Cutaneous Melanoma (Deadline: 31 October 2022)
- New Insights into Hepatocellular Carcinoma (Deadline: 31 October 2022)
- Contribution of Cancer-Targeting Drugs toward Faster Clinical Application 2.0 (Deadline: 31 October 2022)
- New Prospective in the Treatment of Hepatobiliary Tumors (Deadline: 31 October 2022)
- Non-coding RNAs in Glioblastoma Multiforme (Deadline: 31 October 2022)
- Cancer Metastases: Impact of Epithelial-Mesenchymal Transition, Stem Cell and Microenvironment (Deadline: 31 October 2022)
- Molecular Mechanisms Involved in the Chemopreventive and Anticancer Activity of Pentacyclic Triterpenes 2.0 (Deadline: 31 October 2022)
- Cancer Prevention with Molecular Target Therapies 3.0 (Deadline: 31 October 2022)
- Toward a New Era in the Management of Hepatocellular Carcinoma: Novel Perspective on Therapeutic Options and Biomarkers (Deadline: 31 October 2022)
- Tumor-Host Interactions (Deadline: 31 October 2022)
- Novel Targeted Therapies in Cancer (2022) (Deadline: 31 October 2022)
- State-of-the-Art Molecular Oncology in Chile (Deadline: 31 October 2022)
- Advance in Exosomes in Tumors (Deadline: 31 October 2022)
- Bone Tumors and Soft Tissue Tumors (Deadline: 15 November 2022)
- Molecular Research and New Therapy in Melanoma and Other Skin Cancers (Deadline: 15 November 2022)
- Tumor Microenvironment: Molecular Mechanisms and Signaling Pathways Involved in Metastatic Progression (Deadline: 15 November 2022)
- Immunology in Lymphoma and Lymphoproliferative Diseases (Deadline: 15 November 2022)
- Integrative Oncology: From the Lab to New Therapeutic Possibilities (Deadline: 15 November 2022)
- Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment (Deadline: 15 November 2022)
- Molecular Insight into Ovarian Cancer (Deadline: 15 November 2022)
- Human Papillomavirus and Head and Neck Cancer - Molecular Research (Deadline: 15 November 2022)
- Metabolic Therapies for the Treatment of Cancer (Deadline: 15 November 2022)
- Circulating Cell-Free Nucleic Acids and Cancers 2.0 (Deadline: 16 November 2022)
- Protein Kinases and Cancer: State of the Art (Deadline: 25 November 2022)
- Cancer Immunotherapy: Tumor Microenvironment, Biomarker Discovery and Immune Resistance (Deadline: 30 November 2022)
- MicroRNA as Biomarkers in Cancer Diagnostics and Therapeutics (III) (Deadline: 30 November 2022)
- Genetic and Epigenetic Regulations of Tumor Progression and Metastasis 2.0 (Deadline: 30 November 2022)
- Telomeres, Telomerase and Cancer (Deadline: 30 November 2022)
- Extracellular Vesicles and Cancer (Deadline: 30 November 2022)
- Molecular Mechanisms and Therapies of Lung Cancer and Lung Disease (Deadline: 30 November 2022)
- Skin Cancer and Melanoma 2.0 (Deadline: 30 November 2022)
- Emerging Therapies for Malignant Mesothelioma (Deadline: 30 November 2022)
- Anticancer Drugs Activity and Underlying Mechanism (Deadline: 30 November 2022)
- State-of-the-Art Research on Skin Cancer (Deadline: 30 November 2022)
- TRP Channels in Cancer: New Avenues for Diagnosis, Prognostication, and Therapy (Deadline: 30 November 2022)
- Molecular Targets in Preventing Pancreatic Cancer Progression (Deadline: 30 November 2022)
- New Trends in Neoplastic Processes and Markers (Deadline: 30 November 2022)
- Immunomodulation of Skin Cancer (Deadline: 30 November 2022)
- Molecular Mechanisms and Therapies of Advanced Liver Cancer (Deadline: 30 November 2022)
- Cytotoxicity, Antioxidant and Anticancer Activity of Natural Products (Deadline: 30 November 2022)
- Advance in Targeted Cancer Therapy and Mechanisms of Resistance (Deadline: 30 November 2022)
- Chemotherapeutic Agents in Gynecological Cancers: Drug Design, Development and Therapy (Deadline: 30 November 2022)
- Novel Diagnoses, Therapies and Related Mechanisms of Malignancies (Deadline: 30 November 2022)
- Novel Therapeutic Targets in Cancers (Deadline: 30 November 2022)
- Diabetes and Cancer: Molecular Mechanisms of Pathogenesis and Therapeutic Strategies (Deadline: 30 November 2022)
- Development of New Molecular Targets and Therapeutic Approaches against Multidrug-Resistant Cancers (Deadline: 10 December 2022)
- Semaphorin and Neuropilin Signaling in Cancer (Deadline: 10 December 2022)
- Invasion and Metastasis in Brain Cancer (Deadline: 10 December 2022)
- The Molecular Base of Tumor-Immune Interactions – Challenges and Promises to Beat Cancer (Deadline: 15 December 2022)
- Targeted Therapies: Perspectives of Chemical Synthesis and Molecular In Vivo Interactions (Deadline: 15 December 2022)
- Targeting the Wnt Signaling in Cancer (Deadline: 15 December 2022)
- Skin Cancer: From Pathophysiology to Novel Therapy (Deadline: 15 December 2022)
- Novel Agents and Mechanisms in Acute Leukemias 2.0 (Deadline: 15 December 2022)
- Natural Bioactives on Cellular Mechanisms: Cell-Survival and Apoptosis 2.0 (Deadline: 15 December 2022)
- Precision Medicine in Oncology (Deadline: 15 December 2022)
- Molecular Basis of Radiomics in Oncology (Deadline: 15 December 2022)
- Cancer Immunoediting and beyond 2.0 (Deadline: 20 December 2022)
- Non-Small-Cell Lung Cancer (NSCLC): The Changes of Molecular Immunotherapy and Targeted Therapy (Deadline: 25 December 2022)
- Nanoparticles for Tumor Targeting and Therapy (Deadline: 30 December 2022)
- Self-Seeding Cancer Mechanisms: A New Therapeutic Avenue Unfolds (Deadline: 30 December 2022)
- Ozone Therapy in Cancer Treatment (Deadline: 31 December 2022)
- Non-coding RNA and Cancer: New Treatment Opportunities and Impact on Metastasis and Therapy Resistance (Deadline: 31 December 2022)
- Immunotherapy for Hepatocellular Carcinoma: Recent Findings and Future Perspectives (Deadline: 31 December 2022)
- Proteomics and Its Applications in Cancers 2.0 (Deadline: 31 December 2022)
- Molecular Mechanism of Anti-inflammatory Actions of Natural Components (Deadline: 31 December 2022)
- Irradiation and Anti-cancer Therapies: Future and Challenges (Deadline: 31 December 2022)
- Viruses and Cancers (Deadline: 31 December 2022)
- Role of Phytochemicals and Structural Analogs in Cancer Chemoprevention and Therapeutics (Deadline: 31 December 2022)
- Precision Medicine, Pharmacogenomics and Cancer Treatment (Deadline: 31 December 2022)
- Molecular Insights in Kidney Cancer (Deadline: 31 December 2022)
- Molecular Mechanisms of Targeted Therapy in Cancer (Deadline: 31 December 2022)
- New Insights into Overcoming Drug Resistance in Cancers (Deadline: 31 December 2022)
- Tumor Resistance: Mechanisms and Therapy Advancements (Deadline: 31 December 2022)
- Recent Advances in Breast Cancer Research (Deadline: 31 December 2022)
- Novel Insights into Molecular Biology of Urological Cancers 2.0 (Deadline: 31 December 2022)
- Molecular Biomarkers in Cancer and Their Applications (Deadline: 31 December 2022)
- Tumor Targeting Theranostics (Deadline: 31 December 2022)
- New Anticancer Agents: Design, Synthesis and Evaluation (Deadline: 31 December 2022)
- Ephrin Receptors and Cancer 2.0 (Deadline: 31 December 2022)
- Immunology of Hepatocellular Carcinoma 2022 (Deadline: 31 December 2022)
- Molecular Mechanisms of Action and Cytotoxicity of Potential Anticancer Drugs (Deadline: 20 January 2023)
- Hormones-Dependent Cancers: New Aspects on Biochemistry and Molecular Pathology 4.0 (Deadline: 31 January 2023)
- Biomarkers for Diagnosis and Prognosis in Urological Tumors II (Deadline: 31 January 2023)
- Small Cell Lung Cancer: Advances and Novel Perspective in Molecular and Genetic Landscape (Deadline: 31 January 2023)
- Molecular Biology and Drug-Resistance of Cancer Cells (Deadline: 31 January 2023)
- DNA Damage, DNA Repair, and Cancer 2.0 (Deadline: 31 January 2023)
- Molecular Determinants Involved in the Docking and Uptake of Extracelullar Vesicles in Cancer and Immune System (Deadline: 28 February 2023)
Topical Collections
Following topical collections within this section are currently open for submissions:
- Anticancer Drug Discovery and Development
- Feature Papers in Molecular Oncology
- Frontiers in Neuro-Oncology
- Molecular Advances in Hematology: Toward Personalized Medicine
- State-of-the-Art Molecular Oncology in Israel
- State-of-the-Art Molecular Oncology in Italy
- State-of-the-Art Molecular Oncology in Japan
- State-of-the-Art Molecular Oncology in Korea
- State-of-the-Art Molecular Oncology in Poland
- State-of-the-Art Molecular Oncology in Taiwan
- State-of-the-Art Molecular Oncology in UK